These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32667998)

  • 1. Strategies for Implementation Research to Investigate the Negative Pharmacokinetic Interaction Between Efavirenz and Dolutegravir.
    Morse GD
    Clin Infect Dis; 2021 May; 72(10):1823-1825. PubMed ID: 32667998
    [No Abstract]   [Full Text] [Related]  

  • 2. Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
    Haas DW; Acosta EP
    Clin Infect Dis; 2021 May; 72(10):1820-1822. PubMed ID: 32667979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
    Dorward J; Sookrajh Y; Lessells R; Bulo E; Bodley N; Singh L; Moodley P; Samsunder N; Drain PK; Hayward G; Butler CC; Garrett N
    J Acquir Immune Defic Syndr; 2024 Apr; 95(5):e8-e11. PubMed ID: 38489494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy.
    Griesel R; Kawuma AN; Wasmann R; Sokhela S; Akpomiemie G; Venter WDF; Wiesner L; Denti P; Sinxadi P; Maartens G
    Br J Clin Pharmacol; 2022 Mar; 88(3):883-893. PubMed ID: 34954840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
    Allen Reeves A; Fuentes AV; Caballero J; Thomas JE; Mosley Ii JF; Harrington C
    Sex Transm Infect; 2021 Jun; 97(4):261-267. PubMed ID: 33782144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.
    Banda FM; Powis KM; Sun S; Makhema J; Masasa G; Yee LM; Jao J
    AIDS; 2020 Dec; 34(15):2336-2337. PubMed ID: 32910067
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
    Ochanda PN; Lamorde M; Kintu K; Wang D; Chen T; Malaba T; Myer L; Waitt C; Reynolds H; Khoo S
    AIDS Res Ther; 2022 Jun; 19(1):24. PubMed ID: 35672853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir.
    Zimba S; Mbewe N; Chishimba L; Chomba M; Saylor D
    Trop Doct; 2021 Apr; 51(2):216-218. PubMed ID: 32903146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV.
    van der Wekken-Pas L; Nassiwa S; Malaba T; Lamorde M; Myer L; Waitt C; Reynolds H; Khoo S; He N; van Leeuwen L; Burger D; Wang D; Colbers A
    AIDS; 2024 Jun; 38(7):975-981. PubMed ID: 38277390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
    Maartens G; Boffito M; Flexner CW
    Curr Opin HIV AIDS; 2017 Jul; 12(4):355-358. PubMed ID: 28403028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
    Mellgren Å; Eriksson LE; Reinius M; Marrone G; Svedhem V
    PLoS One; 2020; 15(12):e0242710. PubMed ID: 33362248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How the genomics revolution could finally help Africa.
    Nordling L
    Nature; 2017 Apr; 544(7648):20-22. PubMed ID: 28383002
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement.
    Fabbiani M; Cattaneo D; Lombardi A; Colaneri M; Sambo M; Novati S; Fusi M; Bruno R
    J Antimicrob Chemother; 2020 May; 75(5):1354-1356. PubMed ID: 31976524
    [No Abstract]   [Full Text] [Related]  

  • 17. Modifying dolutegravir to PrEPare for long life.
    Mandarino A
    Commun Biol; 2022 Nov; 5(1):1193. PubMed ID: 36344610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study.
    Weidlich S; Boesecke C; Schneider J; Klinker HHF; Zink A; Balogh A; Wolf E; Bidner H; Spinner CD;
    J Antimicrob Chemother; 2020 Oct; 75(10):3082-3084. PubMed ID: 32634214
    [No Abstract]   [Full Text] [Related]  

  • 19. Dolutegravir and rat whole embryo culture.
    Copp AJ; Greene NDE; Jao J; Zash R; Mohan H; Dontsova V; Serghides L
    Birth Defects Res; 2022 Jan; 114(1):23-24. PubMed ID: 34851540
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.
    Elliot ER; Neary M; Else L; Khoo S; Moyle G; Carr DF; Wang X; Mcclure M; Boffito M; Owen A
    J Antimicrob Chemother; 2020 May; 75(5):1259-1266. PubMed ID: 32011683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.